Cooley advised RAPT Therapeutics, while Davis Polk advised the joint book-running managers in the offering. with a $143.7 million SEC-registered follow-on offering of 4,356,060 shares of…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
